A Blended Psychological Intervention for Depression After Acquired Brain Injury

Sponsor
King's College London (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05788146
Collaborator
(none)
20
1
8

Study Details

Study Description

Brief Summary

1.3 million people in the UK live with an Acquired Brain Injury (ABI) as a result of experiencing a stroke or traumatic brain injury (TBI). Up to 50% of individuals with ABI will experience depression. NICE guidelines recommend Cognitive behaviour therapy (CBT) for depression after ABI. There is growing interest into increasing access to CBT through mHealth technology, including mobile applications.

Objective: Phase 1 of the study aims to investigate whether a blended psychological intervention, using a novel smartphone-based application alongside individual therapy sessions is acceptable and feasible for targeting depression after ABI. Phase 2 of the study aims to use qualitative interviews to better understand the participants' experiences of using the mobile app as part of the intervention.

Methodology: The researchers aim to recruit 20 individuals with ABI, who are experiencing mild-moderate symptoms of depression. Participants will complete outcome measures and cognitive tasks at the beginning of the study. Participants will then receive a six-week blended psychological intervention; engaging the CBT-based mobile app alongside weekly, 30-minute video or telephone sessions for therapeutic and technology support. Participants will then be asked to complete the same outcome measures as completed at the beginning of the study. Participants will then be invited to take part in a 30-minute interview about their experience of using the mobile app as part of the intervention.

Data Analysis: Change scores will be calculated from the data collected as part of phase 1 of the study, to investigate initial efficacy. Recruitment and dropout rates will help determine the feasibility of the blended intervention. In the 2nd phase, qualitative data will be analysed following Ritchie and Lewis (2003)'s Framework Analysis.

Findings: Results from this study will help increase understanding into the acceptability and feasibility of using mHealth technology for treating depression following ABI. If effective, it could help to increase access to psychological interventions for individuals living with ABI. We hope to publish findings in a peer reviewed journal.

Condition or Disease Intervention/Treatment Phase
  • Other: Cognitive Behavioural Therapy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Blended Psychological Intervention for Depression After Acquired Brain Injury Using a Novel Smartphone-based App: a Feasibility and Acceptability Investigation
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Jan 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Blended psychological intervention

Other: Cognitive Behavioural Therapy
A psychological intervention used to target depression

Outcome Measures

Primary Outcome Measures

  1. Patient Health Questionnaire-9 (PHQ-9) [8 weeks]

    This is a validated self report measure for symptoms of low mood. Scores range from 0-27, with higher scores suggestive of increased levels of depression. The change in score within each participant between baseline and end of study will be measured.

Secondary Outcome Measures

  1. Generalised Anxiety Disorder Assessment (GAD-7) [8 weeks]

    This is a validated self report measure for symptoms of anxiety. Scores range from 0-21, with higher scores suggestive of increased levels of anxiety. The change in score within each participant between baseline and end of study will be measured.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis of an acquired brain injury resulting from either stroke (cerebral infarction, intracerebral haemorrhage, or an uncertain pathology) or TBI (closed brain injury, contusions/coup-contrecoup, diffuse axonal injury, intracranial hematomas). If there is a diagnosis of TBI, this will be classified within the moderate range, as determined by clinical information available, as well as self-reported information regarding level of hospital input gained within the screening phase.

  • ABI occurring within the last 5 years.

  • 18 years old or over.

  • Fluency in English adequate enough to engage with the blended intervention.

  • A score equal or greater than 5, but no more than 14 on the Brief Patient Health Questionnaire (PHQ-9), indicating mild-moderate levels of depression.

  • Have access to an iOS or Android app-compatible smartphone for the duration of the study.

Exclusion Criteria:
  • Diagnosed with a mild or severe TBI, as determined by clinical information available as well as self-reported information regarding level of hospital input gained within the screening phase.

  • Inability to consent to take part in the research study.

  • Unable to undergo a verbal interview due to impairment of comprehension.

  • A visual or auditory problem that cannot be corrected and would seriously interfere with participation in the research study.

  • Currently in receipt of other individual psychological therapy

  • Currently enrolled in another clinical trial or research study

  • Have a reading ability or command of English language inadequate for engaging with the blended intervention.

  • Diagnosed with a neurodegenerative disorder, e.g. dementia, Parkinson's disease etc.

  • Active suicidal ideation (as indicated by a score ≥ 2 on item 9 of the PHQ.

  • A score greater than or equal to 20 on the PHQ-9 which indicates a severe level of depression

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • King's College London

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
King's College London
ClinicalTrials.gov Identifier:
NCT05788146
Other Study ID Numbers:
  • KCLGL
First Posted:
Mar 28, 2023
Last Update Posted:
Mar 28, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 28, 2023